Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Subscribe To Our Newsletter & Stay Updated
